Finally, because MEK1 mutation is associated with both BRAF and MEK inhibitor resistance in BRAF V600E melanoma [18], we also tested the MEK1 Q56P A375 melanoma model for resistance to the FDA-approved MEK inhibitor compounds trametinib and binimetinib. Here, MAP2K1 is linked to melanoma.